ALKS · Alkermes plc · Stock research

Current Thesis

The leg being bought is the conversion of a profitable legacy CNS commercial house — VIVITROL, ARISTADA, LYBALVI, and now LUMRYZ — into an orexin-2 receptor (OX2R) sleep franchise built on alixorexton. Since the 2026-08-09 update the operating file has not moved and the price has barely moved with it: the 2026-08-21 close of $48.33 is 1.7% under the 2026-08-07 close of $49.17 and 12.5% below the $55.22 52-week high, with RSI(14) at 43.5 against 39.3 two weeks earlier. The two events that mattered are already in the tape. Q2 2026 revenue printed $496.0M against a $457.8M consensus on 2026-07-28, with adjusted EBITDA $139.2M and adjusted EPS $0.00 versus a forecast $0.02 loss, while Q3 was guided to $450–470M against a $472.8M consensus and FY2026 was merely affirmed at $1.730–1.840B versus $1.812B consensus. On 2026-08-05 the FDA approved Takeda's ORZEYFUL (oveporexton) for narcolepsy type 1 — the first OX2R agonist ever cleared — and the stock has not made a new high in the sixteen sessions since.

The narrative is maturing, and the dating is unchanged from the last note with two weeks of confirming price action added. Discovery ended with Vibrance-2 on 2026-06-17; the sell-side finished repricing between 2026-06-09 and 2026-07-29 (RBC $56, TD Cowen $50, Needham $54→$61→$62, Piper Sandler $65 on 07-28, JPMorgan Neutral $61 and Baird $58 on 07-29); the class's largest external validation on 2026-08-05 produced no new high. It still works — the trailing three-month price change is +31.3% — but that figure has decayed from +40.5% as of 2026-08-07 with the stock down only 1.7% over the same span, which is the June gap rolling toward the back edge of the window rather than fresh selling. Not saturated, because the June breakout shelf has not been given back; not accelerating, because the headline flow since 2026-08-05 has been confirmatory and thin.

Bullish and bearish views on Alkermes plc

The model's bull view on Alkermes plc (ALKS), in brief: 2026-08-05: FDA approval of Takeda's ORZEYFUL for NT1 removes mechanism risk for the whole OX2R class. The bear view: The Q3 guide of $450–470M sits below the $472.8M consensus (2026-07-28) — the first quantitative crack in the "base compounds while the pipeline matures" leg, and it lands before any orexin revenue exists. Both cases follow in full.

Bull Case

• 2026-08-05: FDA approval of Takeda's ORZEYFUL for NT1 removes mechanism risk for the whole OX2R class. The label carries no boxed hepatic warning and advises avoiding use in Child-Pugh C — a favourable read-through against the class overhang left by Takeda's halted TAK-994.
• 2026-07-28: Q2 proprietary product sales $411.7M, +34% YoY — VIVITROL $124.5M, ARISTADA $96.7M, LYBALVI $94.0M (+12% YoY), LUMRYZ $96.6M in its first full quarter post-acquisition. Cash and investments ~$690M at quarter-end. The commercial base funds the orexin programme without a raise at current burn.
• 2026-07-13: an interim analysis of the alixorexton long-term extension showed sustained wakefulness improvement out to nine months of treatment — durability evidenced across time rather than at a single acute timepoint.
• 2026-06-17: Vibrance-2 met dual primary endpoints in narcolepsy type 2, the segment ORZEYFUL's approved NT1 label does not cover. 2026-06-15: US orphan designation in idiopathic hypersomnia and EC orphan designation in narcolepsy.
• Dated pipeline optionality from the 2026-07-28 call: ALKS 7290 (ADHD) top-line "by end of third quarter", a Phase 1b in ADHD patients in Q4, Vibrance-3 (IH) completion in Q4 2026, a LUMRYZ sNDA for IH by year-end, and Phase 3 Brilliance completion expected in 2027.
• Rating distribution remains skewed positive: 14 buy / 3 hold / 1 sell and a $56 consensus target as of 2026-08-03, against the 2026-08-21 close of $48.33.

Bear Case

• The Q3 guide of $450–470M sits below the $472.8M consensus (2026-07-28) — the first quantitative crack in the "base compounds while the pipeline matures" leg, and it lands before any orexin revenue exists.
• 2026-06-29: BofA's Jason Gerberry cut to Underperform with a $38 target after a 92% YTD rally, citing VIVITROL loss of exclusivity in January 2027 and Takeda's TAK-360 in NT2/IH. Published targets span $38 to $72 (as of 2026-08-03) — a fair-value band nearly as wide as the share price, which mechanically widens realized range around any print.
• Takeda holds the launch. ORZEYFUL becomes available only after DEA scheduling, expected within 90 days of the 2026-08-05 approval; alixorexton's Phase 3 Brilliance studies do not complete until 2027. Every quarter of that gap is share Takeda can take in NT1.
• Balance sheet: the Avadel/LUMRYZ transaction added $1.525B of term loans due 2031 against ~$690M of cash and a FY2026 adjusted EBITDA guide of $75–95M, itself revised down on 2026-07-28 for a contingent-consideration charge alongside a GAAP net loss guide of $95–115M.
• Price behaviour after 2026-08-05 is the cleanest bear datapoint available: the single largest validation the mechanism will ever get produced no new high, and sixteen sessions later the stock is lower.

Setup & Price Structure

The range since mid-June runs roughly from the $45.76 pre-Vibrance-2 high — the shelf the June gap cleared — to the $55.22 52-week high. The 2026-08-21 close of $48.33 sits in the lower half of that band, 5.6% above the shelf and 12.5% below the high. RSI(14) at 43.5 is neither extended nor washed out; it has ticked up from 39.3 on 2026-08-07 while price slipped, so the decline is decelerating rather than extending.

Crowding and positioning observables, stated as observables: rating skew is 14 buy / 3 hold / 1 sell with a $56 consensus and a $38–$72 dispersion (as of 2026-08-03), which leaves little room for further upgrade flow to act as the marginal bid; the next scheduled earnings event is roughly two months out (~late October), so there is no imminent print compressing the tape; and trailing three-month momentum is decaying on calendar mechanics — by late September the 2026-06-17 gap exits the three-month window, at which point momentum screens de-rank the name regardless of what price does. That last point is an inference from the return arithmetic, not a measured flow.

The structural question is simply whether the $45.76 shelf holds through a catalyst-light stretch. Below it, the June re-rate is a round trip; above the $55.22 high, the market is paying for Vibrance-3 in advance.

Catalyst Calendar (next 30 days)

• No confirmed company-dated event falls between 2026-08-22 and 2026-09-21. The window is catalyst-light by the company's own guidance.
• ~2026-09-30 (est.) — ALKS 7290 (ADHD) top-line, guided "by end of third quarter" on the 2026-07-28 call. Could print inside the window; the guided boundary is the quarter end. First readout from a non-orexin asset.
• Undated, bounded ~2026-11-03 — DEA scheduling of Takeda's ORZEYFUL, expected within 90 days of the 2026-08-05 approval. This can land at any point and gates the first orexin launch.
• ~2026-10-28 (est.) — Q3 2026 results; tests whether the $450–470M guide was conservative and which end of the affirmed $1.730–1.840B FY range is live.
• ~2026-12-15 (est.) — Vibrance-3 idiopathic hypersomnia Phase 2 completion, the next genuine binary.
• ~2026-12-31 (est.) — LUMRYZ sNDA filing for idiopathic hypersomnia.
• 2027-01-31 — VIVITROL loss-of-exclusivity window on a franchise that produced $124.5M in Q2 2026.

What Would Change Our Mind

The structure that has to hold is the June breakout shelf at $45.76 — the pre-Vibrance-2 high the 2026-06-17 gap cleared. Losing it converts a validated-mechanism re-rate into a round trip, and the gradeable version of that is a weekly close below $44. Two non-price conditions would do the same work: FY2026 tracking toward the $1.730B low end of the affirmed range at the ~October print (particularly with VIVITROL declining sequentially ahead of the January 2027 exclusivity date), or a Vibrance-3 miss in Q4 2026, which removes the idiopathic-hypersomnia indication that differentiates alixorexton from an NT1-only approved label. A third, softer condition: if the ~2026-09-30 ALKS 7290 readout comes and goes without moving the stock and DEA scheduling passes with Takeda launching into NT1 unopposed, the frame flips toward saturated — well-covered, fully targeted, and dependent on a single Q4 readout. On the other side, a weekly close above $55.22 on Vibrance-3 or an early ALKS 7290 result would argue the marginal buyer returned before the binary rather than after it.

Correlation Notes

• The name trades as part of an orexin complex, not as a standalone. Takeda (4502.T) owns the only approved OX2R agonist; Centessa (CNTA) carries ORX750; Jazz (JAZZ) and Harmony Biosciences (HRMY) are the incumbent oxybate and WAKIX franchises that LUMRYZ and alixorexton are taking share from. A clinical or commercial datapoint at any of them reprices the class.
• LUMRYZ came from the Avadel transaction, so the sleep-franchise leg and the $1.525B term-loan leg are the same decision — commercial execution in narcolepsy and the leverage question are not independent variables.
• The legacy base (VIVITROL, ARISTADA, LYBALVI) is US-payer and addiction/psychiatry-exposed, which correlates with Medicaid coverage policy rather than with biotech beta.
• Beyond that, standard small/mid-cap biotech factor exposure applies: rate-sensitive multiple, XBI-style drawdown beta, and no index-driven bid to lean on between catalysts.